Document is current

Article History

Received: 10 March 2022

Accepted: 19 May 2022

First Online: 6 June 2022

Declarations

:

: The study was approved by the Comité de Protection des Personnes du Sud Ouest et Outre Mer 4 (RCB ID: 2018-A00176-49). Written and oral information about the study was given to patients or their families prior enrolment. Informed consent was obtained from all patients or their relatives.

: Not applicable.

: Maxens Decavèle reports personal fees (for congress registration) from ISIS Medical. Thomas Similowski reports personal fees from AstraZeneca France, personal fees from Boerhinger Ingelheim France, personal fees and non-financial support from Novartis France, personal fees from TEVA France, personal fees from Chiesi France, personal fees from Lungpacer Inc, personal fees from ADEP Assistance, grants from Air Liquide Medical Systems, outside the submitted work. Alexandre Demoule reports grants, personal fees and non-financial support from Philips, personal fees from Baxter, personal fees and non-financial support from Fisher & Paykel, grants from French Ministry of Health, personal fees from Getinge, grants, personal fees and non-financial support from Respinor, grants, personal fees and non-financial support from Lungpacer, personal fees from Lowenstein, personal fees from Gilead, outside the submitted work. Martin Dres reports expertise fees, travel expenses, research contract from Lungpacer, research contract from Bioserenity, and congress registration fees from Dräger, outside the submitted work. Capucine Morélot-Panzini reports personal fees from Astra-Zeneca, GSK, SOS Oxygène, ADEP, ISIS, Resmed, Chiesi, Menarini, Vivisol, Air Liquide, Lowenstein, Fisher & Paykel, outside the submitted work. Julien Mayaux reports personal fees (for congress registration) from Gilead France. Emmanuel Rozenberg, Elise Morawiec and Marie-Cécile Niérat, have no conflicts of interests to declare.